Search clinical trials for: Jardiance

Total 133 results

Royal Perth Hospital

Recruiting

Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans (EMPA-SNS)

Obesity | Type 2 Diabetes Mellitus | Metabolic Syndrome

Australia
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (SLIDE)

NAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLD

United States
University Hospital Tuebingen

Withdrawn

Empagliflozin Effect on Glucose Toxicity

Type2 Diabetes Mellitus

Germany
Boehringer Ingelheim
Eli Lilly and Company

Active, not recruiting

Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Heart Failure

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Diabetes Mellitus, Type 2

United States, Canada, Thailand, Korea, Republic of, United Kingdom, China, Germany, Israel, Mexico, Argentina, Brazil, Colombia, Puerto Rico, Russian Federation
Inventiva Pharma

Active, not recruiting

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND)

Diabetes Mellitus, Type 2 | NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Netherlands, United Kingdom
Boehringer Ingelheim

Active, not recruiting

Emp-Activity: Empagliflozin Functional Capacity

Heart Failure

Czechia, Switzerland, Poland, Hungary, Romania, Bulgaria
Humanis Saglık Anonim Sirketi

Completed

Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

Type2 Diabetes Mellitus

India
Boehringer Ingelheim

Completed

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Diabetes Mellitus, Type 2

Bulgaria, Czechia, Hungary, Poland, Russian Federation
RenJi Hospital

Terminated

Efficacy and Safety of Empagliflozin in NODAT

Kidney Transplant; Complications | New Onset Diabetes After Transplant

China
Boehringer Ingelheim

Completed

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together (InPedILD®)

Healthy

Brazil
Boehringer Ingelheim
Eli Lilly and Company

Active, not recruiting

Comparative Effectiveness of Empagliflozin in the US

Diabetes Mellitus, Type 2

United States
The Deutsche Diabetes Forschungsgesellschaft e.V.
Boehringer Ingelheim

Completed

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes (EmLiFa)

Type 2 Diabetes | Non-alcoholic Fatty Liver Disease

Germany
Columbia University

Completed

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

Transthyretin Amyloid Cardiomyopathy

United States
Ohio State University
Diacomp

Withdrawn

Empagliflozin in Adolescent Diabetes

type1diabetes

United States
Unity Health Toronto
Boehringer Ingelheim; Canadian Medical and Surgical Knowledge Translation Research... and other collaborators

Completed

Empagliflozin and Cardiac Remodelling in People Without Diabetes (EMPA-HEART 2)

Cardiovascular Diseases | Left Ventricular Hypertrophy

Canada, Taiwan
Ain Shams University

Completed

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Pharmacokinetics | Pharmacogenomic

Egypt
University of Catanzaro

Completed

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study) (FIORE)

Type 2 Diabetes | Cardiovascular Risk Factor

Italy
Asmaa Abdelfattah Elsayed

Completed

Follow-up of NAFLD Patients With MRI-PDFF

NAFLD | Diabetes Type 2

Egypt
RWTH Aachen University
Boehringer Ingelheim

Terminated

EMPA Acute Heart Failure

Diabetes Mellitus, Type 2 | Acute Heart Failure

Germany
Caroline M Kistorp
Rigshospitalet, Denmark; Herlev and Gentofte Hospital; Danish Heart Foundation

Completed

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk (SIMPLE)

Type2 Diabetes Mellitus

Denmark
National Institute on Aging (NIA)

Completed

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Physiological Effects of Drugs | Hypoglycemic Agents | Empaglifozin | Sodium-Glucose Transporter 2 Inhibitors

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Heart Failure

United States, Spain, Korea, Republic of, China, Germany, Belgium, Australia, Singapore, Canada, Italy, Argentina, Hungary, Czechia, Poland, Netherlands, Japan, United Kingdom, Mexico, Romania, Brazil, India, South Africa, Colombia
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
Pusan National University Yangsan Hospital

Completed

Effect of Garlic Extracts on Changes in Cerebral Blood Flow

Healthy

Korea, Republic of
Sanofi

Completed

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Diabetes Mellitus

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
M.H.H. Kramer

Active, not recruiting

Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES (RACELINES)

Type2 Diabetes

Netherlands
National Medical Research Center for Cardiology...
Ministry of Health of the Russian Federation

Completed

Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Heart Failure, Diastolic

Russian Federation
Saint Luke's Health System

Completed

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure (EMBRACE-HF)

Heart Failure

United States
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
Handok Inc.

Completed

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Type 2 Diabetes Mellitus

Korea, Republic of
Amsterdam UMC, location VUmc

Completed

Renohemodynamic Effects of Combined empagliflOzin and LosARtan (RECOLAR)

Diabetes Mellitus, Type 2 | Diabetic Kidney Disease

Netherlands
Mario Negri Institute for Pharmacological Research
Boehringer Ingelheim

Withdrawn

SGLT2 Inhibitors in Glomerular Hyperfiltration (EMPATHY)

Obesity | Non-diabetic Chronic Kidney Disease
University of Dundee
British Heart Foundation

Completed

SGLT2 Inhibition in Combination With Diuretics in Heart Failure (RECEDE-CHF)

Heart Failure | Type 2 Diabetes Mellitus

United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

Heart Failure

United Kingdom
Shire

Completed

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

ADHD

United States
Boehringer Ingelheim

Completed

Regulatory Request NIS in Korea

Diabetes Mellitus, Type 2

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Heart Failure

United States, Spain, Canada, Korea, Republic of, China, Germany, Belgium, Australia, Italy, United Kingdom, Argentina, Hungary, Czechia, Poland, Netherlands, Japan, Mexico, India, Brazil, France
Boehringer Ingelheim

Completed

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of
Yonsei University

Completed

Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

Type 2 Diabetes Mellitus

Korea, Republic of
Johannes Gutenberg University Mainz
Boehringer Ingelheim

Completed

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics (EmDia)

Diabetes Mellitus, Type 2 | Diastolic Dysfunction

Germany
University of Pisa

Unknown

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections. (UTI-flog)

Type 2 Diabetes | Urinary Tract Infections

Italy
Singapore General Hospital
Duke-NUS Graduate Medical School

Terminated

Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN) ((MEDiaN))

Diabetic Nephropathies

Singapore
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

Heart Failure

United States, Spain, Canada, Germany, Greece, Australia, Sweden, Italy, Norway, Poland, Portugal
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

Heart Failure

United States, Spain, Canada, Germany, Australia, Greece, Italy, Norway, Poland, Portugal, Sweden
University of California, San Francisco

Completed

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

Type 2 Diabetes Mellitus

United States
University Hospital, Geneva

Completed

Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis

Keratitis; Infectious Disease (Manifestation)

Switzerland
Yonsei University

Completed

Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

Type2 Diabetes Mellitus

Korea, Republic of

Search clinical trials for: Jardiance

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations